Drugs / RS1 AAV Vector
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02317887 | Feb 2015 → Apr 2024 | X-linked disease, retinoschisis | VegaVect, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RS1 AAV Vector | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02317887 ↗ |
| Known as | AAV-RS1 | “Objective: To evaluate the safety and tolerability of ocular AAV-RS1 vector (AAV8-scRS/IRBPhRS) gene transfer to the retina of participants affected with X-linked juvenile...” NCT02317887 ↗ |
| Known as | AAV8-RS1 | “intravitreally administered AAV8-RS1 gene replacement therapy for XLRS participants” PMID 34390869 ↗ Aug 2021 |
| Known as | AAV8-scRS/IRBPhRS | “Objective: To evaluate the safety and tolerability of ocular AAV-RS1 vector (AAV8-scRS/IRBPhRS) gene transfer to the retina of participants affected with X-linked juvenile...” NCT02317887 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated virus vectors encoding RS1 gene” PMID 36227606 ↗ Oct 2022 |
| Route | Intravitreal | “by intravitreal injection” NCT02317887 ↗ |
| Target | RS1 | “introduce a healthy RS1 gene into eye cells” NCT02317887 ↗ |